Last reviewed · How we verify

IV ondansetron hydrochloride

GlaxoSmithKline · Phase 3 active Small molecule

Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting. Used for Prevention of nausea and vomiting induced by chemotherapy, Prevention of post-operative nausea and vomiting (PONV), Prevention of radiation-induced nausea and vomiting.

At a glance

Generic nameIV ondansetron hydrochloride
SponsorGlaxoSmithKline
Drug class5-HT3 receptor antagonist
Target5-HT3 receptor
ModalitySmall molecule
Therapeutic areaOncology, Gastroenterology
PhasePhase 3

Mechanism of action

Ondansetron is a selective 5-HT3 receptor antagonist that inhibits serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. By blocking these receptors, it prevents the emetic signals that trigger nausea and vomiting, particularly those induced by chemotherapy, radiation, or post-operative conditions. The IV formulation provides rapid onset of action for acute antiemetic coverage.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: